stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) EBITDA
GSK PLC Sponsored ADR's EBITDA for fiscal 2025 was $13.5B, up 60.9% from $8.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $12.2B. Over the past ten years it has ranged from $5.9B (fiscal 2016) to $18.3B (fiscal 2015); the current reading is higher than 91% of that period. GSK PLC Sponsored ADR ranks 11th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $13.5B | 60.88% |
| FY2024 | $8.4B | (25.31%) |
| FY2023 | $11.2B | 5.95% |
| FY2022 | $10.6B | 24.46% |
| FY2021 | $8.5B | (34.47%) |
| FY2020 | $13.0B | 9.63% |
| FY2019 | $11.9B | 21.16% |
| FY2018 | $9.8B | 26.49% |
| FY2017 | $7.7B | 30.70% |
| FY2016 | $5.9B | (67.58%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $3.9B | 5.19% |
| Jun 2026 | $3.7B | 0.07% |
| Mar 2026 | $3.7B | 333.32% |
| Dec 2025 | $857.0M | (81.01%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| AZN AstraZeneca PLC compare | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR | $12.2B |
| SNY Sanofi compare | $11.1B |
| BIIB Biogen Inc. compare | $2.3B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GSK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement